Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. ResMed, Inc.
  6. News
  7. Summary
    RMD   US7611521078

RESMED, INC.

(RMD)
  Report
Delayed Nyse  -  05/18 04:00:01 pm EDT
191.41 USD   -3.25%
04:06pEVEN 2 HOURS OF PAP THERAPY PER NIGHT BENEFITS SLEEP APNEA SUFFERERS : ResMed Study
GL
04:05pEVEN 2 HOURS OF PAP THERAPY PER NIGHT BENEFITS SLEEP APNEA SUFFERERS : ResMed Study
AQ
05/17INSIDER SELL : Resmed
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ResMed Receives Price Target Boost to $234 From $227 From RBC on 'Positive Implications" From Philips Update; Underperform Kept

01/13/2022 | 10:27am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ON SEMICONDUCTOR CORPORATION -4.56% 55.83 Delayed Quote.-17.80%
PHILIPS NV -0.77% 23.725 Real-time Quote.-27.59%
RESMED, INC. -3.25% 191.41 Delayed Quote.-26.52%
All news about RESMED, INC.
04:06pEVEN 2 HOURS OF PAP THERAPY PER NIGH : ResMed Study
GL
04:05pEVEN 2 HOURS OF PAP THERAPY PER NIGH : ResMed Study
AQ
05/17INSIDER SELL : Resmed
MT
05/11RESMED INC : Change in Directors or Principal Officers, Financial Statements and Exhibits ..
AQ
05/11RESMED, INC. : Ex-dividend day for
FA
05/05Insulet Reports Q1 Profit , Names New CEO
MT
05/05ResMed Announces Leadership Change
GL
05/05ResMed Inc. Announces Management Changes
CI
05/04INSIDER SELL : Resmed
MT
05/02TRANSCRIPT : ResMed Inc. Presents at 24th Annual Macquarie Australia Conference, May-03-20..
CI
More news
Analyst Recommendations on RESMED, INC.
More recommendations
Financials (USD)
Sales 2022 3 581 M - -
Net income 2022 780 M - -
Net Debt 2022 375 M - -
P/E ratio 2022 36,1x
Yield 2022 0,88%
Capitalization 28 000 M 28 000 M -
EV / Sales 2022 7,92x
EV / Sales 2023 6,93x
Nbr of Employees 7 970
Free-Float 77,1%
Chart RESMED, INC.
Duration : Period :
ResMed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESMED, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 191,41 $
Average target price 243,13 $
Spread / Average Target 27,0%
EPS Revisions
Managers and Directors
Michael J. Farrell Director-Business Development
Robert Andrew Douglas Vice President-Corporate Marketing
Brett A. Sandercock Chief Financial Officer
Peter C. Farrell Non-Executive Chairman
Carlos M. Nunez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
RESMED, INC.-26.52%28 939
THERMO FISHER SCIENTIFIC-19.16%217 105
DANAHER CORPORATION-24.33%178 236
INTUITIVE SURGICAL, INC.-37.33%80 830
SIEMENS HEALTHINEERS AG-14.68%66 343
EDWARDS LIFESCIENCES CORPORATION-24.82%60 552